Literature DB >> 18620092

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Rachel M A Linger1, Amy K Keating, H Shelton Earp, Douglas K Graham.   

Abstract

Tyro-3, Axl, and Mer constitute the TAM family of receptor tyrosine kinases (RTKs) characterized by a conserved sequence within the kinase domain and adhesion molecule-like extracellular domains. This small family of RTKs regulates an intriguing mix of processes, including cell proliferation/survival, cell adhesion and migration, blood clot stabilization, and regulation of inflammatory cytokine release. Genetic or experimental alteration of TAM receptor function can contribute to a number of disease states, including coagulopathy, autoimmune disease, retinitis pigmentosa, and cancer. In this chapter, we first provide a comprehensive review of the structure, regulation, biologic functions, and downstream signaling pathways of these receptors. In addition, we discuss recent evidence which suggests a role for TAM receptors in oncogenic mechanisms as family members are overexpressed in a spectrum of human cancers and have prognostic significance in some. Possible strategies for targeted inhibition of the TAM family in the treatment of human cancer are described. Further research will be necessary to evaluate the full clinical implications of TAM family expression and activation in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620092      PMCID: PMC3133732          DOI: 10.1016/S0065-230X(08)00002-X

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  174 in total

1.  A Web-based data warehouse on gene expression in human malignant melanoma.

Authors:  Balazs Györffy; Hermann Lage
Journal:  J Invest Dermatol       Date:  2006-08-31       Impact factor: 8.551

2.  Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases.

Authors:  Anouk Caraux; Qingxian Lu; Nadine Fernandez; Sylvain Riou; James P Di Santo; David H Raulet; Greg Lemke; Claude Roth
Journal:  Nat Immunol       Date:  2006-06-04       Impact factor: 25.606

Review 3.  Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases.

Authors:  Sassan Hafizi; Björn Dahlbäck
Journal:  Cytokine Growth Factor Rev       Date:  2006-06-05       Impact factor: 7.638

4.  A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.

Authors:  Susan Sather; Karla D Kenyon; Jerry B Lefkowitz; Xiayuan Liang; Brian C Varnum; Peter M Henson; Douglas K Graham
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 5.  Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily.

Authors:  Sassan Hafizi; Björn Dahlbäck
Journal:  FEBS J       Date:  2006-10-25       Impact factor: 5.542

6.  TAM receptor function in the retinal pigment epithelium.

Authors:  Dipti Prasad; Carla Vanina Rothlin; Patrick Burrola; Tal Burstyn-Cohen; Qingxian Lu; Pablo Garcia de Frutos; Greg Lemke
Journal:  Mol Cell Neurosci       Date:  2006-08-09       Impact factor: 4.314

7.  Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells.

Authors:  Pradip Sen; Mark A Wallet; Zuoan Yi; Yingsu Huang; Michael Henderson; Clayton E Mathews; H Shelton Earp; Glenn Matsushima; Albert S Baldwin; Roland M Tisch
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

8.  Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.

Authors:  A K Keating; D B Salzberg; S Sather; X Liang; S Nickoloff; A Anwar; D Deryckere; K Hill; D Joung; K K Sawczyn; J Park; D Curran-Everett; L McGavran; L Meltesen; L Gore; G L Johnson; D K Graham
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

9.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  Twist mediates suppression of inflammation by type I IFNs and Axl.

Authors:  M Nusrat Sharif; Drazen Sosic; Carla V Rothlin; Erin Kelly; Greg Lemke; Eric N Olson; Lionel B Ivashkiv
Journal:  J Exp Med       Date:  2006-07-10       Impact factor: 14.307

View more
  306 in total

1.  Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Jing Liu; Chao Yang; Catherine Simpson; Deborah Deryckere; Amy Van Deusen; Michael J Miley; Dmitri Kireev; Jacqueline Norris-Drouin; Susan Sather; Debra Hunter; Victoria K Korboukh; Hari S Patel; William P Janzen; Mischa Machius; Gary L Johnson; H Shelton Earp; Douglas K Graham; Stephen V Frye; Xiaodong Wang
Journal:  ACS Med Chem Lett       Date:  2012-02-09       Impact factor: 4.345

Review 2.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 3.  Impaired clearance of apoptotic cells in germinal centers: implications for loss of B cell tolerance and induction of autoimmunity.

Authors:  Ziaur S M Rahman
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 4.  Pathways of oncogene-induced senescence in human melanocytic cells.

Authors:  Rajat Bansal; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

5.  Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Authors:  Amy K Keating; Grace K Kim; Ashley E Jones; Andrew M Donson; Kathryn Ware; Jean M Mulcahy; Dana B Salzberg; Nicholas K Foreman; Xiayuan Liang; Andrew Thorburn; Douglas K Graham
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

Review 6.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

7.  Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

Authors:  Weihe Zhang; Andrew L McIver; Michael A Stashko; Deborah DeRyckere; Brian R Branchford; Debra Hunter; Dmitri Kireev; Michael J Miley; Jacqueline Norris-Drouin; Wendy M Stewart; Minjung Lee; Susan Sather; Yingqiu Zhou; Jorge A Di Paola; Mischa Machius; William P Janzen; H Shelton Earp; Douglas K Graham; Stephen V Frye; Xiaodong Wang
Journal:  J Med Chem       Date:  2013-11-20       Impact factor: 7.446

8.  AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; John P Coan; Hannah E Pearson; Harsh Bahrar; Tyler L Fowler; Bryan P Bednarz; Sandeep Saha; David Yang; Parkash S Gill; Mark W Lingen; Vassiliki Saloura; Victoria M Villaflor; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Clin Cancer Res       Date:  2015-03-12       Impact factor: 12.531

9.  Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.

Authors:  Kinga Pénzes; Christine Baumann; István Szabadkai; László Orfi; György Kéri; Axel Ullrich; Robert Torka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Opposing Roles of Tyrosine Kinase Receptors Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated Nephritis.

Authors:  Yuxuan Zhen; Stephen O Priest; Wen-Hai Shao
Journal:  J Immunol       Date:  2016-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.